Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209506 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02209506 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 23 participants.
The verdict
NCT02209506, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple oral dosing of MLN3126 in ascending doses in healthy non-Japanese and Japanese participants.
Interventions
- DRUG MLN3126
- DRUG MLN3126 Matched Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209506
The ClinicalTrials.gov registry entry for NCT02209506 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MLN3126 is the first listed.
NCT02209506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02209506 about?
NCT02209506 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants". The purpose of this study is to evaluate the safety and tolerability of single and multiple oral dosing of MLN3126 in ascending doses in healthy non-Japanese and Japanese participants.
What is the current status of trial NCT02209506?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2014-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02209506?
The interventions under investigation include: MLN3126 (DRUG), MLN3126 Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT02209506?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.